

Please add the following claims:

Sub C1  
19. (New) A non-gene therapy-based method for inhibiting the growth of a tumor in a human subject comprising delivering to the tumor one or more  $\alpha$  (1,3) galactosyl epitope-containing cells, thereby inhibiting the growth of the tumor in the subject.

20. (New) The method of claim 19, wherein the tumor is in the peritoneal cavity.

B1  
21. (New) The method of claim 19, wherein the one or more  $\alpha$  (1,3) galactosyl epitope-containing cells is derived from a mammal.

22. (New) The method of claim 21, wherein the mammal is a mouse.

23. (New) The method of claim 20, wherein the tumor is a solid tumor.

24. (New) The method of claim 23, wherein the solid tumor is the result of a carcinoma selected from the group consisting of ovarian carcinoma, fallopian carcinoma, and peritoneal carcinoma.

25. (New) The method of claim 19, further comprising administering one or more chemotherapeutic agents to the subject following delivery to the tumor of the one or more  $\alpha$  (1,3) galactosyl epitope-containing cells.

26. (New) A non-gene therapy-based method for inhibiting the growth of a tumor in a human subject comprising delivering to the tumor one or more  $\alpha$  (1,3) galactosyl epitope-containing cells, wherein the tumor is in the peritoneal cavity, thereby inhibiting the growth of the tumor in the subject.

27. (New) The method of claim 26, wherein the one or more  $\alpha$  (1,3) galactosyl epitope-containing cells is derived from a mammal.

28. (New) The method of claim 27, wherein the mammal is a mouse.

29. (New) The method of claim 26, wherein the tumor is a solid tumor.

30. (New) The method of claim 26, further comprising administering one or more chemotherapeutic agents to the subject following delivery to the tumor of the one or more  $\alpha$  (1,3) galactosyl epitope-containing cells.

31. (New) The method of claim 29, wherein the solid tumor is the result of a carcinoma selected from the group consisting of ovarian carcinoma, fallopian carcinoma, and peritoneal carcinoma.

32. (New) A non-gene therapy-based method for inhibiting the growth of a tumor in a human subject, the method comprising:  
delivering to the tumor a murine cell line; and

administering one or more chemotherapeutic agents to the subject following delivery to the tumor of the murine cell line,  
thereby inhibiting the growth of the tumor in the subject.

33. (New) The method of claim 32, wherein the murine cell line is a murine retroviral vector producer cell line.

34. (New) The method of claim 33, wherein the retroviral vector is derived from the Moloney murine leukemia virus.